✦ AI AI Company Comparison

Benchling vs Faire — IPO & Funding Comparison

Side-by-side IPO readiness, funding history, and valuation comparison. Data sourced by TechStackIPO.

⚠️
Some data on this page may be outdated. We're verifying.
Data for Benchling last verified: Jul 7, 2026. Data for Faire last verified: Jul 3, 2026.
Metric Benchling Faire
Valuation$8.5B$12.4B
Total Funding$912M$1.7B
IPO StatusPublicPrivate
SectorBiotechnologyE-commerce
StagePublicSeries H
HeadquartersSan Francisco, CASan Francisco, CA
CEOSajith WickramasekaraMax Rhodes
The IPO Stack Newsletter

Get Tuesday's IPO moves + one deep-dive in your inbox

Scores, valuations, and signals for Benchling, Faire, and 370+ companies. 5-min read every Tuesday.

Benchling

Benchling is the R&D cloud platform for life sciences teams to design, track, and analyze experiments — the operating system for biotech and pharmaceutical R&D globally. Valued at $6.1B with $500M+ raised, Benchling is used by 10 of the top 20 pharmaceutical companies including Pfizer, Novartis, and Regeneron. Major healthtech IPO candidate competing with Schrödinger and Dotmatics in the $30B+ life sciences software market.

IndustryBiotechnology
StagePublic
IPO StatusPublic
Valuation$8.5B
Total Funding$912M
HeadquartersSan Francisco, CA

Faire

Faire is the wholesale marketplace connecting 700K+ independent retailers with 100K+ emerging brands — the B2B commerce platform for the indie retail economy. Valued at $12.4B with $1.7B raised, Faire processes billions in annual GMV and is the dominant wholesale marketplace globally. IPO candidate as B2B commerce digitisation continues to disrupt traditional wholesale distribution — a $50B+ global market.

IndustryE-commerce
StageSeries H
IPO StatusPrivate
Valuation$12.4B
Total Funding$1.7B
HeadquartersSan Francisco, CA

Get the Full Report on Any Company — One-Time $19

Complete funding history, cap table, S-1 analysis, and investor breakdown for any company. Instant PDF download.

Get All 375+ Reports — $49/mo

Or buy any single company report for $19

Frequently Asked Questions

What is the Benchling vs Faire valuation in 2026? +

Benchling is valued at $8.5B. Faire is valued at $12.4B. Both figures are based on the most recent funding rounds tracked by TechStackIPO.

Which is more likely to IPO first — Benchling or Faire? +

Benchling filed an S-1 in May 2026 and is actively in the IPO pipeline. Faire filed an S-1 in April 2026 and is actively in the IPO pipeline. Track both companies on TechStackIPO for S-1 filings, roadshow announcements, and IPO date updates.

How much has each company raised in total funding? +

Benchling has raised $912M. Faire has raised $1.7B.

Are Benchling and Faire in the same sector? +

Benchling operates in Biotechnology, while Faire operates in E-commerce.

What are the key differences between Benchling and Faire as investments? +

Benchling is a Biotechnology company valued at $8.5B with $912M raised. Faire is a E-commerce company valued at $12.4B with $1.7B raised. See TechStackIPO's full side-by-side comparison for IPO readiness scores, funding timelines, and investor access options.

How can I invest in Benchling or Faire before their IPO? +

Accredited investors can access pre-IPO shares in Benchling and Faire through secondary market platforms, pre-IPO funds, and broker-dealer platforms that facilitate private company transactions. TechStackIPO's marketplace section tracks available access options for both companies. Pre-IPO investments carry higher risk and limited liquidity.